BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35032814)

  • 1. Development and validation of a transcriptomics-based gene signature to predict distant metastasis and guide induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Liu SL; Sun XS; Chen QY; Liu ZX; Bian LJ; Yuan L; Xiao BB; Lu ZJ; Li XY; Yan JJ; Yan SM; Li JM; Bei JX; Mai HQ; Tang LQ
    Eur J Cancer; 2022 Mar; 163():26-34. PubMed ID: 35032814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
    Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
    Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma protein-based signature predicts distant metastasis and induction chemotherapy benefit in Nasopharyngeal Carcinoma.
    Liang Y; Li J; Li Q; Tang L; Chen L; Mao Y; He Q; Yang X; Lei Y; Hong X; Zhao Y; He S; Guo Y; Wang Y; Zhang P; Liu N; Li Y; Ma J
    Theranostics; 2020; 10(21):9767-9778. PubMed ID: 32863958
    [No Abstract]   [Full Text] [Related]  

  • 5. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
    Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
    Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nomogram to predict survival and guide individualized induction chemotherapy in T3-4N1M0 nasopharyngeal carcinoma.
    Jiang YT; Chen KH; Liang ZG; Yang J; Qu S; Li L; Zhu XD
    Curr Probl Cancer; 2022 Dec; 46(6):100897. PubMed ID: 36162165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
    Li SW; Wang H; Liu ML; Zhang HB; Xiang YQ; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
    Med Oncol; 2013 Mar; 30(1):322. PubMed ID: 23254962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
    Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
    Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
    Lei Y; Li YQ; Jiang W; Hong XH; Ge WX; Zhang Y; Hu WH; Wang YQ; Liang YL; Li JY; Cho WCS; Yun JP; Zeng J; Chen JW; Liu LZ; Li L; Chen L; Xie FY; Li WF; Mao YP; Liu X; Chen YP; Tang LL; Sun Y; Liu N; Ma J
    J Natl Cancer Inst; 2021 Apr; 113(4):471-480. PubMed ID: 33094348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
    Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy.
    Wen DW; Li ZX; Chen FP; Lin L; Peng BY; Kou J; Zheng WH; Yang XL; Xu SS; Sun Y; Zhou GQ
    Oral Oncol; 2020 Aug; 107():104675. PubMed ID: 32361563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
    Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
    Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Luo WJ; Zou WQ; Liang SB; Chen L; Zhou GQ; Peng H; Li WF; Liu X; Sun Y; Lin AH; Ma J; Mao YP
    Radiother Oncol; 2021 Feb; 155():56-64. PubMed ID: 33039423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI-Based Deep-Learning Model for Distant Metastasis-Free Survival in Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang L; Wu X; Liu J; Zhang B; Mo X; Chen Q; Fang J; Wang F; Li M; Chen Z; Liu S; Chen L; You J; Jin Z; Tang B; Dong D; Zhang S
    J Magn Reson Imaging; 2021 Jan; 53(1):167-178. PubMed ID: 32776391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics-based nomogram guides adaptive de-intensification in locoregionally advanced nasopharyngeal carcinoma following induction chemotherapy.
    Wang SX; Yang Y; Xie H; Yang X; Liu ZQ; Li HJ; Huang WJ; Luo WJ; Lei YM; Sun Y; Ma J; Chen YF; Liu LZ; Mao YP
    Eur Radiol; 2024 Mar; ():. PubMed ID: 38514481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI-based radiomics nomogram may predict the response to induction chemotherapy and survival in locally advanced nasopharyngeal carcinoma.
    Zhao L; Gong J; Xi Y; Xu M; Li C; Kang X; Yin Y; Qin W; Yin H; Shi M
    Eur Radiol; 2020 Jan; 30(1):537-546. PubMed ID: 31372781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Li WF; Chen L; Sun Y; Ma J
    Chin J Cancer; 2016 Nov; 35(1):94. PubMed ID: 27846913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
    Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.